Study of an experimental drug for pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests an experimental drug called 2-HOBA in people with pulmonary arterial hypertension (PAH). The goal is to see if it can help improve symptoms and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a specific type of PAH (idiopathic, heritable, from a simple heart defect, or from drugs/toxins).
- Your PAH medications have been stable for at least 3 months before joining.
- Your lung function is mostly normal (FEV1 at least 60% of predicted, with no more than mild issues on lung imaging).
- You are able to walk (you do not use a wheelchair or walker full-time and are not restricted to bed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
This Phase 2 trial tests whether 2-HOBA can improve how “good cholesterol” (HDL) works in people with familial hypercholesterolemia (FH). If HDL works better, it may help lower heart risk markers. You would need to meet several heart, health, and medication-related safety checks.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.